# COgnitioN With VERiciGuat Evaluation in Heart Failure

Study · id `cardio:ct-nct06601465` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06601465](<https://clinicaltrials.gov/study/NCT06601465>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06601465

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06601465. Randomized; no masking; primary purpose treatment. Start 2025-06-03 (actual); primary completion 2028-07-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06601465, source copy `cardio:ctgov-nct06601465-2026-08-25`, retrieved 2026-10-26)
- Started: 2025-06-03 (actual) (ClinicalTrials.gov record NCT06601465, source copy `cardio:ctgov-nct06601465-2026-08-25`, retrieved 2026-10-26)
- Primary completion: 2028-07-16 (anticipated) (ClinicalTrials.gov record NCT06601465, source copy `cardio:ctgov-nct06601465-2026-08-25`, retrieved 2026-10-26)
- Completion: 2028-07-16 (anticipated) (ClinicalTrials.gov record NCT06601465, source copy `cardio:ctgov-nct06601465-2026-08-25`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT06601465, source copy `cardio:ctgov-nct06601465-2026-08-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06601465-2026-08-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: COgnitioN With VERiciGuat Evaluation in Heart Failure
- Acronym: CONVERGE-HF
- Condition: Heart Failure
- Condition: Cognitive Impairment
- Intervention (Drug): Vericiguat
- Lead sponsor: University of Alberta
- Lead sponsor class: OTHER
- Collaborator: Ottawa Heart Institute Research Corporation
- Collaborator class: OTHER
- Collaborator: Heart and Stroke Foundation of Canada
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University of Alberta (`cardio:org-university-of-alberta`)
- Registry lists this organization as a collaborator: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)
- Registry lists this organization as a collaborator: Heart and Stroke Foundation of Canada (`cardio:org-heart-and-stroke-foundation-of-canada`)

## Provenance

Content hash: 9a023e147cd49bf48cb4859d6a5a2d7a2238b926385e1345a188eb6b0e94b18a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
